

Special Issue

Personalizing Medicine by Sex, Gender and Hormonal Status: Progress, Opportunities and Challenges

Message from the Guest Editors

Biological sex, gender, and gonadal hormone status have a substantial influence on the incidence, prevalence, presentation, treatment response, and outcome of diverse disorders and pathologies across all medical fields. Despite increasing recognition of the importance of these variables, demographic data collected from patients and participants in clinical trials do not routinely include information on gonadal hormone status (e.g., puberty, stage of menstrual cycle, menopause, or andropause). In this Special Issue, practitioners and investigators in diverse fields of medicine summarize their experience and outline opportunities and challenges in the use of sex, gender, and gonadal hormone status to personalize and improve the diagnosis and treatment of conditions including diabetes, breast cancer, epilepsy, schizophrenia, and brain injury.

Guest Editors

Prof. Anat Biegon

Department of Radiology, Director, Center on Gender, Hormones and Health, Stony Brook University, School of Medicine, Stony Brook, NY 11794-2565, USA

Prof. Dr. Mary V. Seeman

Department of Psychiatry, University of Toronto, Toronto, ON M5S 1A8, Canada

Deadline for manuscript submissions

closed (10 August 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/73757

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).